Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: A randomized, double-blind, placebo-controlled, crossover study

Michael Miller, Paul S. Bachorik, Brian W. McCrindle, Peter O. Kwiterovich

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the efficacy of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol (HDL-C) levels. Patients and Methods: Fourteen men with low levels of HDL-C but desirable total cholesterol levels received gemfibrozil in a randomized, double-blind, placebo-controlled, crossover trial. The men were placed on a National Cholesterol Education Program Step-Two Diet. They were randomly assigned to receive placebo and gemfibrozil each for 3 months, with a 1-month washout period between phases. Results: Overall, gemfibrozil increased the total HDL-C concentration by 9.2% (p = 0.001), reduced triglyceride (TG) levels by 38% (p <0.01), and significantly lowered the total cholesterol:HDL-C ratio (p = 0.01). Those with fasting TG levels of 1.07 mmol L (95 mg/dL) or greater had a significant elevation in the HDL-C level (14.6%, p = 0.005) and a reduction in TG levels (50%, p = 0.002) with gemfibrozil; those with fasting TG levels less than 1.07 mmol L had a smaller incease in the HDL-C level (4.1%, p > 0.05) and a smaller reduction in TG levels (15%, p = 0.02). There were no significant differences in the plasma levels of low density lipoprotein-cholesterol, HDL2-C, apolipoproteins (apo) A-I and B, or Lp(a). HDL3-C and ano A-II levels rose slightly. The adverse effects attributable to gemfibrozil were minimal. Conclusion: In men with desirable total cholesterol levels, gemfibrozil raises HDL-C and lowers TG levels to a similar extent as reported for hyperlipidemic men in the Helsinki Heart Study. These lipid-altering effects were most pronounced in those with the highest fasting TG levels.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalAmerican Journal of Medicine
Volume94
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Gemfibrozil
LDL Cholesterol
Cross-Over Studies
HDL Cholesterol
Placebos
Triglycerides
Cholesterol
Apolipoprotein A-I
Apolipoproteins B
Fasting
Diet
Lipids
Education

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol : A randomized, double-blind, placebo-controlled, crossover study. / Miller, Michael; Bachorik, Paul S.; McCrindle, Brian W.; Kwiterovich, Peter O.

In: American Journal of Medicine, Vol. 94, No. 1, 1993, p. 7-12.

Research output: Contribution to journalArticle

Miller, Michael ; Bachorik, Paul S. ; McCrindle, Brian W. ; Kwiterovich, Peter O. / Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol : A randomized, double-blind, placebo-controlled, crossover study. In: American Journal of Medicine. 1993 ; Vol. 94, No. 1. pp. 7-12.
@article{eaece21206bb43ef84d6c262cebe3e92,
title = "Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: A randomized, double-blind, placebo-controlled, crossover study",
abstract = "Purpose: To evaluate the efficacy of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol (HDL-C) levels. Patients and Methods: Fourteen men with low levels of HDL-C but desirable total cholesterol levels received gemfibrozil in a randomized, double-blind, placebo-controlled, crossover trial. The men were placed on a National Cholesterol Education Program Step-Two Diet. They were randomly assigned to receive placebo and gemfibrozil each for 3 months, with a 1-month washout period between phases. Results: Overall, gemfibrozil increased the total HDL-C concentration by 9.2{\%} (p = 0.001), reduced triglyceride (TG) levels by 38{\%} (p <0.01), and significantly lowered the total cholesterol:HDL-C ratio (p = 0.01). Those with fasting TG levels of 1.07 mmol L (95 mg/dL) or greater had a significant elevation in the HDL-C level (14.6{\%}, p = 0.005) and a reduction in TG levels (50{\%}, p = 0.002) with gemfibrozil; those with fasting TG levels less than 1.07 mmol L had a smaller incease in the HDL-C level (4.1{\%}, p > 0.05) and a smaller reduction in TG levels (15{\%}, p = 0.02). There were no significant differences in the plasma levels of low density lipoprotein-cholesterol, HDL2-C, apolipoproteins (apo) A-I and B, or Lp(a). HDL3-C and ano A-II levels rose slightly. The adverse effects attributable to gemfibrozil were minimal. Conclusion: In men with desirable total cholesterol levels, gemfibrozil raises HDL-C and lowers TG levels to a similar extent as reported for hyperlipidemic men in the Helsinki Heart Study. These lipid-altering effects were most pronounced in those with the highest fasting TG levels.",
author = "Michael Miller and Bachorik, {Paul S.} and McCrindle, {Brian W.} and Kwiterovich, {Peter O.}",
year = "1993",
doi = "10.1016/0002-9343(93)90113-4",
language = "English (US)",
volume = "94",
pages = "7--12",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol

T2 - A randomized, double-blind, placebo-controlled, crossover study

AU - Miller, Michael

AU - Bachorik, Paul S.

AU - McCrindle, Brian W.

AU - Kwiterovich, Peter O.

PY - 1993

Y1 - 1993

N2 - Purpose: To evaluate the efficacy of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol (HDL-C) levels. Patients and Methods: Fourteen men with low levels of HDL-C but desirable total cholesterol levels received gemfibrozil in a randomized, double-blind, placebo-controlled, crossover trial. The men were placed on a National Cholesterol Education Program Step-Two Diet. They were randomly assigned to receive placebo and gemfibrozil each for 3 months, with a 1-month washout period between phases. Results: Overall, gemfibrozil increased the total HDL-C concentration by 9.2% (p = 0.001), reduced triglyceride (TG) levels by 38% (p <0.01), and significantly lowered the total cholesterol:HDL-C ratio (p = 0.01). Those with fasting TG levels of 1.07 mmol L (95 mg/dL) or greater had a significant elevation in the HDL-C level (14.6%, p = 0.005) and a reduction in TG levels (50%, p = 0.002) with gemfibrozil; those with fasting TG levels less than 1.07 mmol L had a smaller incease in the HDL-C level (4.1%, p > 0.05) and a smaller reduction in TG levels (15%, p = 0.02). There were no significant differences in the plasma levels of low density lipoprotein-cholesterol, HDL2-C, apolipoproteins (apo) A-I and B, or Lp(a). HDL3-C and ano A-II levels rose slightly. The adverse effects attributable to gemfibrozil were minimal. Conclusion: In men with desirable total cholesterol levels, gemfibrozil raises HDL-C and lowers TG levels to a similar extent as reported for hyperlipidemic men in the Helsinki Heart Study. These lipid-altering effects were most pronounced in those with the highest fasting TG levels.

AB - Purpose: To evaluate the efficacy of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol (HDL-C) levels. Patients and Methods: Fourteen men with low levels of HDL-C but desirable total cholesterol levels received gemfibrozil in a randomized, double-blind, placebo-controlled, crossover trial. The men were placed on a National Cholesterol Education Program Step-Two Diet. They were randomly assigned to receive placebo and gemfibrozil each for 3 months, with a 1-month washout period between phases. Results: Overall, gemfibrozil increased the total HDL-C concentration by 9.2% (p = 0.001), reduced triglyceride (TG) levels by 38% (p <0.01), and significantly lowered the total cholesterol:HDL-C ratio (p = 0.01). Those with fasting TG levels of 1.07 mmol L (95 mg/dL) or greater had a significant elevation in the HDL-C level (14.6%, p = 0.005) and a reduction in TG levels (50%, p = 0.002) with gemfibrozil; those with fasting TG levels less than 1.07 mmol L had a smaller incease in the HDL-C level (4.1%, p > 0.05) and a smaller reduction in TG levels (15%, p = 0.02). There were no significant differences in the plasma levels of low density lipoprotein-cholesterol, HDL2-C, apolipoproteins (apo) A-I and B, or Lp(a). HDL3-C and ano A-II levels rose slightly. The adverse effects attributable to gemfibrozil were minimal. Conclusion: In men with desirable total cholesterol levels, gemfibrozil raises HDL-C and lowers TG levels to a similar extent as reported for hyperlipidemic men in the Helsinki Heart Study. These lipid-altering effects were most pronounced in those with the highest fasting TG levels.

UR - http://www.scopus.com/inward/record.url?scp=0027530595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027530595&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(93)90113-4

DO - 10.1016/0002-9343(93)90113-4

M3 - Article

C2 - 8420303

AN - SCOPUS:0027530595

VL - 94

SP - 7

EP - 12

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1

ER -